VEGF-controlled release within a bone defect from alginate/chitosan/PLA-H scaffolds.
VEGF and its receptors constitute the key signaling system for angiogenic activity in tissue formation, but a direct implication of the growth factor in the recruitment, survival and activity of bone forming cells has also emerged. For this reason, we developed a composite (alginate/chitosan/PLA-H) system that controls the release kinetics of incorporated VEGF to enhance neovascularization in bone healing. VEGF release kinetics and tissue distribution were determined using iodinated ((125)I) growth factor. VEGF was firstly encapsulated in alginate microspheres. To reduce the high in vitro burst release, the microspheres were included in scaffolds. Matrices were prepared with alginate (A-1, A-2), chitosan (CH-1, CH-2) or by coating the CH-1 matrix with a PLA-H (30 kDa) film (CH-1-PLA), the latter one optimally reducing the in vitro and in vivo burst effect. The VEGF in vitro release profile from CH-1-PLA was characterized by a 13% release within the first 24h followed by a constant release rate throughout 5 weeks. For VEGF released from composite scaffolds in vitro, bioactivity was maintained above 90% of the expected value. Despite the fact that the in vivo release rate was slightly faster, a good in vitro-in vivo correlation was found. The VEGF released from CH-1 and CH-1-PLA matrices implanted into the femurs of rats remained located around the implantation site with a negligible systemic exposure. These scaffolds provided a bone local GF concentration above 10 ng/g during 2 and 5 weeks, respectively, in accordance to the in vivo release kinetics. Our data show that the incorporation of VEGF into the present scaffolds allows for a controlled release rate and localization of the GF within the bone defect.
De la Riva
Beatriz
B
Department of Chemical Engineering and Pharmaceutical Technology, University of La Laguna, La Laguna, Spain.
Nowak
Christian
C
Sánchez
Esther
E
Hernández
Antonio
A
Schulz-Siegmund
Michaela
M
Pec
Martina K
MK
Delgado
Araceli
A
Evora
Carmen
C
D000464:Alginates / Q000008:administration & dosage* / Q000737:chemistry; D000818:Animals; D001847:Bone Diseases / Q000188:drug therapy* / Q000378:metabolism; D048271:Chitosan / Q000008:administration & dosage* / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology; D020723:Glucuronic Acid / Q000008:administration & dosage / Q000737:chemistry; D006603:Hexuronic Acids / Q000008:administration & dosage / Q000737:chemistry; D006801:Humans; D011091:Polyesters / Q000008:administration & dosage* / Q000737:chemistry; D051381:Rats; D054457:Tissue Scaffolds; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage* / Q000737:chemistry
D000464:Alginates; D003692:Delayed-Action Preparations; D006603:Hexuronic Acids; D011091:Polyesters; D042461:Vascular Endothelial Growth Factor A; C033616:poly(lactide); D020723:Glucuronic Acid; D048271:Chitosan